Neurocrine Biosciences (NBIX) Liabilities and Shareholders Equity (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $5.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 37.77% year-over-year to $5.4 billion; the trailing twelve-month figure through Jun 2026 stood at $19.2 billion (up 29.2% YoY), and the FY2025 full-year result was $4.6 billion, up 24.55% from the prior year.
• Liabilities and Shareholders Equity grew to $5.4 billion in Q2 2026 per NBIX's latest filing, from $4.9 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $5.4 billion in Q2 2026 and bottomed at $2.0 billion in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $3.4 billion across 5 years, with a median of $3.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity grew 2.52% in 2022, then jumped 47.15% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.4 billion in 2022, then surged by 37.27% to $3.3 billion in 2023, then climbed by 14.37% to $3.7 billion in 2024, then gained by 24.55% to $4.6 billion in 2025, then increased by 15.71% to $5.4 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5.4 billion, $4.9 billion, and $4.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.